Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Editas Medicine, Inc. Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events May 02, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration May 01, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers BMY EDIT Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting April 22, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates February 28, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events February 21, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Participate in Upcoming Investor Conferences January 31, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference January 08, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 December 13, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar December 11, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Third Quarter 2023 Results and Business Updates November 03, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar November 02, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events October 27, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease October 16, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer September 25, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer September 25, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Upcoming Investor Events August 30, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Second Quarter 2023 Results and Business Updates August 02, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization July 27, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update July 26, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer July 24, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Pricing of Offering of Common Stock June 14, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Offering of Common Stock June 14, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial June 09, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia June 06, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Reports Inducement Grant to New Chief Financial Officer May 18, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer May 16, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress May 11, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces First Quarter 2023 Results and Business Updates May 05, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data May 01, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.